Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge | Research Square
Background Nirmatrelvir, an inhibitor of the main protease of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a significant decrease in the risk of progression to severe disease in symptomatic high-risk patients infected with the B.1.617.2 (delta) varian...
